SG10201407936XA - Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) - Google Patents

Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Info

Publication number
SG10201407936XA
SG10201407936XA SG10201407936XA SG10201407936XA SG10201407936XA SG 10201407936X A SG10201407936X A SG 10201407936XA SG 10201407936X A SG10201407936X A SG 10201407936XA SG 10201407936X A SG10201407936X A SG 10201407936XA SG 10201407936X A SG10201407936X A SG 10201407936XA
Authority
SG
Singapore
Prior art keywords
treatment
sle
antibodies
lupus erythematosus
systemic lupus
Prior art date
Application number
SG10201407936XA
Other languages
English (en)
Inventor
Frank Osterroth
Christoph Uherek
Christoph Bruecher
Peter Röttgen
Benjamin Daelken
André Engling
Chantal Zuber
Niklas Czeloth
Andrea Wartenberg-Demand
Marcus Gutscher
Judith Wessels-Kranz
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0920942A external-priority patent/GB0920942D0/en
Priority claimed from GB0920933A external-priority patent/GB0920933D0/en
Priority claimed from GB0920940A external-priority patent/GB0920940D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of SG10201407936XA publication Critical patent/SG10201407936XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201407936XA 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle) SG10201407936XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0920942A GB0920942D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920933A GB0920933D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920940A GB0920940D0 (en) 2009-11-30 2009-11-30 Agent for treating disease

Publications (1)

Publication Number Publication Date
SG10201407936XA true SG10201407936XA (en) 2015-01-29

Family

ID=43798505

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201407936XA SG10201407936XA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
SG10201407935YA SG10201407935YA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201407935YA SG10201407935YA (en) 2009-11-30 2010-11-30 Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Country Status (17)

Country Link
US (4) US8852871B2 (fr)
EP (2) EP2470208A1 (fr)
JP (2) JP6005519B2 (fr)
KR (2) KR101802260B1 (fr)
CN (2) CN102811736B (fr)
AU (2) AU2010323036B2 (fr)
BR (2) BR112012012917A2 (fr)
CA (2) CA2782004A1 (fr)
CO (1) CO6561779A2 (fr)
CR (2) CR20120358A (fr)
IL (2) IL219955A (fr)
MX (2) MX350206B (fr)
NZ (2) NZ600894A (fr)
RU (2) RU2581812C2 (fr)
SG (2) SG10201407936XA (fr)
WO (2) WO2011064398A1 (fr)
ZA (1) ZA201204843B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102811736B (zh) 2009-11-30 2016-01-20 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
CN106913865A (zh) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
JP2016526014A (ja) * 2013-04-24 2016-09-01 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０組成物及びその使用
EP3010527B1 (fr) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Méthode d'évaluation de l'identité et de la stabilité d'une protéine
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
EP3105251A4 (fr) * 2014-02-10 2017-11-15 Merck Sharp & Dohme Corp. Anticorps qui se lient à la protéine tau humaine et dosage pour quantifier la protéine tau humaine au moyen des anticorps
JP2017535783A (ja) * 2014-11-28 2017-11-30 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ センサー表面でアナライト−リガンド結合を測定するための方法
DK3233915T3 (da) * 2014-12-15 2024-09-30 Morphosys Ag Antistoffer til il-17c
WO2016126615A1 (fr) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
WO2016191587A1 (fr) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
WO2017035232A1 (fr) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
AU2016362777B2 (en) 2015-12-04 2020-01-30 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2019072566A1 (fr) 2017-10-10 2019-04-18 Biotest Ag Combinaison d'anticorps anti-il10 et anti-pd1 pour le traitement du cancer
AR114112A1 (es) * 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
WO2021206766A1 (fr) 2020-04-09 2021-10-14 Children's Hospital Medical Center Biomarqueurs d'infection par sras-cov-2 et leurs utilisations
EP3892280A3 (fr) 2020-04-09 2022-01-12 Children's Hospital Medical Center Biomarqueurs d'une infection sars-cov-2 et leurs utilisations
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
IL302871A (en) 2020-11-18 2023-07-01 Astrazeneca Ab Saving steroids
AU2022242840A1 (en) * 2021-03-23 2023-09-28 Organogenesis, Inc. Methods kits and compositions for characterizing an anti-inflammatory response of a product
KR20240114801A (ko) * 2023-01-17 2024-07-25 한양대학교 산학협력단 Il-10 수용체에 특이적으로 결합하는 항체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0567586T3 (da) * 1991-01-16 1995-12-04 Schering Corp Anvendelse af interleukin-10 ved adoptiv immunterapi af cancer
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ES2138976T3 (es) 1991-08-06 2000-02-01 Schering Corp Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
DE19529026C2 (de) 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
EP2301966A1 (fr) * 2002-12-16 2011-03-30 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
MX346172B (es) 2007-08-29 2017-03-10 Sanofi - Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
CN102811736B (zh) * 2009-11-30 2016-01-20 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体

Also Published As

Publication number Publication date
KR101802261B1 (ko) 2017-11-28
AU2010323037A1 (en) 2012-07-19
CR20120358A (es) 2013-01-23
CN102811736A (zh) 2012-12-05
KR20120115289A (ko) 2012-10-17
CA2782007C (fr) 2018-07-24
EP2470208A1 (fr) 2012-07-04
CA2782004A1 (fr) 2011-06-03
IL219954A (en) 2016-10-31
CR20120359A (es) 2013-01-25
CA2782007A1 (fr) 2011-06-03
US20120321618A1 (en) 2012-12-20
US9540436B2 (en) 2017-01-10
US20150218270A1 (en) 2015-08-06
RU2012127380A (ru) 2014-01-10
AU2010323036A1 (en) 2012-07-19
AU2010323037B2 (en) 2015-01-29
RU2581812C2 (ru) 2016-04-20
WO2011064399A1 (fr) 2011-06-03
IL219955A (en) 2016-08-31
EP2470209A1 (fr) 2012-07-04
WO2011064398A1 (fr) 2011-06-03
CN102811736B (zh) 2016-01-20
US8852871B2 (en) 2014-10-07
JP2013511994A (ja) 2013-04-11
RU2587622C2 (ru) 2016-06-20
AU2010323036B2 (en) 2015-01-29
US20120321617A1 (en) 2012-12-20
MX350206B (es) 2017-08-28
MX2012006198A (es) 2012-06-19
IL219954A0 (en) 2012-07-31
MX2012006197A (es) 2012-06-19
NZ600899A (en) 2014-09-26
BR112012012912A2 (pt) 2016-10-25
ZA201204843B (en) 2020-02-26
MX343228B (es) 2016-10-26
US9605066B2 (en) 2017-03-28
CN102711829A (zh) 2012-10-03
US8956607B2 (en) 2015-02-17
CN102711829B (zh) 2016-03-16
SG10201407935YA (en) 2015-01-29
NZ600894A (en) 2014-09-26
US20150064179A1 (en) 2015-03-05
BR112012012917A2 (pt) 2016-10-25
JP2013511995A (ja) 2013-04-11
IL219955A0 (en) 2012-07-31
CO6561779A2 (es) 2012-11-15
EP2470209B1 (fr) 2020-01-01
KR20120103664A (ko) 2012-09-19
KR101802260B1 (ko) 2017-11-28
JP6005519B2 (ja) 2016-10-12
RU2012127381A (ru) 2014-01-10

Similar Documents

Publication Publication Date Title
SG10201407936XA (en) Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
NZ607969A (en) Cd33 binding agents
NZ594985A (en) Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
WO2015091914A3 (fr) Anticorps murins caninisés dirigés contre le récepteur pd-1 humain
MX354243B (es) Polipeptidos anticuerpos que antagonizan cd40.
EA035160B9 (ru) Антитела к st2 и их применение
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
NZ724296A (en) Antibodies for treatment of cancer expressing claudin 6
MX362039B (es) Anticuerpos anti-il-23.
MX2009012812A (es) Proteinas estructurales de una mutacion del parvovirus como vacunas.
NZ593905A (en) Il-1 binding proteins
NZ708033A (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof
WO2012064836A9 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MX2013013832A (es) Proteínas de unión receptoras fc.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2012065110A3 (fr) Analogues de cystéine s-protégés et composés associés
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.
WO2012097238A3 (fr) Antagonistes de l'il-27 utilisables en vue du traitement de maladies inflammatoires
CA2839668C (fr) Epitope de l'antigene de surface du virus de l'hepatite b et son utilisation
IL277056A (en) Methods for purifying antibodies
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
EP2491142A4 (fr) Production d'une réponse immunitaire pour réduire le risque de développer la brucellose
IN2014DN09951A (fr)